Associated tags: Retina, Biomedicine, Clearside, SCS, Eye, Patient, Choroid, Pharmaceutical industry, Pharming, AMD, Axitinib, Webcast, OASIS
Locations: NEW YORK, NY, ET, BI, LONDON, ALPHARETTA, GA, US, MERRILL, EUROPE
DAS,
AMD,
Boehringer Ingelheim,
Research,
Johnson & Johnson,
Conference,
Webcast,
Conference call,
Patient,
M&A,
CPT,
Eye,
Pharming,
Conditional sentence,
Data analysis,
MBA,
Drug delivery,
Clinical trial,
Biotechnology,
ARVO,
Visual acuity,
Pharmaceutical industry ALPHARETTA, Ga., May 09, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
Key Points:
- ET -
ALPHARETTA, Ga., May 09, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
- License and other revenue for the first quarter of 2024 was $230,000, compared to $4,000 for the first quarter of 2023.
- Other expense for the first quarter of 2024 was $1.5 million, compared to $0 for the first quarter of 2023.
- Clearside’s management will host a webcast and conference call today at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.
ALPHARETTA, Ga., May 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer, will participate in a Fireside Chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024, at 9:30 a.m.
Key Points:
- ALPHARETTA, Ga., May 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer, will participate in a Fireside Chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024, at 9:30 a.m.
- ET in New York, NY.
- A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations .
- An archive of the webcast will be available for three months.
AMD,
Sale,
Executive,
SVB Securities,
Yale University,
Therapy,
History,
Eye,
Acquisition,
Pharming,
Retina,
Biotechnology,
Management “We are delighted to welcome Tony to our Board of Directors as we build on our leadership in delivering therapeutics to the suprachoroidal space,” said Clay Thorp, Chair of the Clearside Board of Directors.
Key Points:
- “We are delighted to welcome Tony to our Board of Directors as we build on our leadership in delivering therapeutics to the suprachoroidal space,” said Clay Thorp, Chair of the Clearside Board of Directors.
- Most recently, Mr. Gibney served as the Executive Vice President, Chief Business & Strategy officer of Iveric Bio, Inc. until the company’s acquisition by Astellas Pharma Inc. in July 2023.
- Before Achillion, Mr. Gibney was a Managing Director and Co-head of the biotechnology investment banking team at Leerink Partners LLC, and Managing Director of Merrill Lynch’s healthcare group.
- He currently serves on the boards of directors of LAPIX Therapeutics, Inc. and InflaRx N.V. Mr. Gibney received a B.A.
ALPHARETTA, Ga., April 02, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer, will participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 3:00 p.m.
Key Points:
- ALPHARETTA, Ga., April 02, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer, will participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 3:00 p.m.
- ET.
- A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations .
- An archive of the webcast will be available for three months.
DAS,
Retina,
University,
Moorfields Eye Hospital,
Pathology,
Oligonucleotide,
Ranibizumab,
Data analysis,
Partnership,
Business,
Boehringer Ingelheim,
DME,
Patient,
Pharming,
Research,
Royal College of Ophthalmologists,
Cell biology,
Diabetic retinopathy,
C3,
University College London,
MBA,
Eye,
Johnson & Johnson,
Janssen,
Drug development,
John Radcliffe Hospital,
AMD,
CLS,
University of Oxford,
Royal college,
Geographic atrophy,
Stargardt disease,
DMI,
Pharmaceutical industry ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.
Key Points:
- ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.
- George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer of Clearside, commented, “Victor is a well-known and well-respected retinal clinician and scientist, who is a strategically focused and visionary leader.
- We are delighted to have him join the Clearside team.
- “With the upcoming ODYSSEY data and extensive partnership portfolio, this is an exciting time to join Clearside.
Patient,
G&A,
BioCryst Pharmaceuticals,
Eye,
Drug delivery,
Clinical trial,
AAO,
Extension,
Webcast,
Pharming,
CPT,
Safety,
Disease,
SPA,
American Academy of Ophthalmology,
Compass,
Insurance,
Diabetic retinopathy,
Conference call,
Aura,
AMD,
TKI,
CLS,
FDA,
Administration,
Conference,
SCS,
DME,
American Academy,
OASIS,
Injection,
Research and development,
Axitinib,
Pharmaceutical industry ALPHARETTA, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.
Key Points:
- License Revenue: License and other revenue for the fourth quarter of 2023 was $6.3 million, compared to $0.3 million for the fourth quarter of 2022.
- Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $6.3 million, compared to $5.0 million for the fourth quarter of 2022.
- General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2023 were $2.9 million, compared to $3.2 million for the fourth quarter of 2022.
- Other Expense: Non-cash interest expense for the fourth quarter of 2023 was $2.3 million, compared to $2.0 million for the fourth quarter of 2022.
Retrieved on:
Thursday, February 29, 2024
Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
Key Points:
- Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
- The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations .
- The live call can be accessed by dialing 888-506-0062 (U.S.) or 973-528-0011 (international) and entering conference code: 694916.
- The Company suggests participants join 15 minutes in advance of the event.
Retrieved on:
Wednesday, February 7, 2024
The offer price for one share of common stock and accompanying warrant to purchase one share of common stock will be $1.35.
Key Points:
- The offer price for one share of common stock and accompanying warrant to purchase one share of common stock will be $1.35.
- The offering is expected to close on or about February 9, 2024, subject to the satisfaction of customary closing conditions.
- The gross proceeds to Clearside from this offering are expected to be approximately $15.0 million, before deducting the placement agent’s fees and other offering expenses payable by Clearside.
- Clearside intends to use the net proceeds from this offering for working capital and general corporate purposes.
Retrieved on:
Thursday, December 14, 2023
ALPHARETTA, Ga., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that it has completed randomization in its ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in neovascular age-related macular degeneration (wet AMD). Topline data results are expected in the third quarter of 2024.
Key Points:
- ALPHARETTA, Ga., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that it has completed randomization in its ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in neovascular age-related macular degeneration (wet AMD).
- Topline data results are expected in the third quarter of 2024.
- “As we continue to make significant progress in our ODYSSEY trial, we are optimistic about the potential benefits of CLS-AX, our proprietary suspension of axitinib for suprachoroidal injection,” said George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer.
- “Axitinib is a highly-potent tyrosine kinase inhibitor (TKI) that achieves pan-VEGF blockade, directly inhibiting VEGF receptors-1, -2, and -3 with high potency and specificity.
Retrieved on:
Monday, November 13, 2023
Potential,
Visual acuity,
Patient,
Research,
American Medical Association,
Targeted drug delivery,
Conference,
American Academy of Ophthalmology,
R,
Diabetes,
Diabetic retinopathy,
Webcast,
Literature,
American Academy,
Administration,
DME,
G&A,
Research and development,
Physician,
Paratriathlon,
Retina,
Drug delivery,
Pharming,
Eye,
Intravitreal injection,
BioCryst Pharmaceuticals,
SCS,
Edema,
AAO,
Melanoma,
AURA,
Solubility,
Partnership,
AMD,
Clearside,
Bausch & Lomb,
OASIS,
Axitinib,
Plasma,
Clinical trial,
CLS,
CPT,
Conference call,
UME,
Injection,
HIV disease progression rates,
Pharmaceutical industry,
Nursing,
Video game ALPHARETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
Key Points:
- ET -
ALPHARETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
- Other Income: Other income for the third quarter of 2023 was $0.4 million, compared to $0.2 million for the third quarter of 2022.
- Other Expense: Non-cash interest expense for the third quarter of 2023 was $2.6 million, compared to $1.3 million in the third quarter of 2022.
- Clearside’s management will host a webcast and conference call today at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.
